Breast CancerNCT03072316
Impact of Radiotherapy on Patients Undergoing DIEP Flap Breast Reconstruction
An observational study of Breast Cancer, run by Royal Marsden NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
The investigators intend to undertake a study to investigate the effect of radiotherapy on deep inferior epigastric perforator flap reconstructions (DIEP). Adjuvant post-mastectomy radiotherapy (PMRT) is offered to women at high risk of chest wall recurrence. Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Breast Cancer
- What is being tested?
- 3D surface imaging, semi-structured interview and applanation tonometry
- How many people
- 300 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 14 Jan 2016to 14 Jan 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Study population: Any patient who has undergone unilateral DIEP reconstruction for breast cancer at the Royal Marsden NHS Foundation Trust
Who may be able to join
- Women who have undergone one of the treatment sequences above (a) - (d)
- Patient groups:
- Unilateral skin sparing mastectomy (SSM) with immediate DIEP flap reconstruction and PMRT (cases)
- Unilateral SSM with immediate DIEP flap reconstruction and no PMRT (controls)
- Unilateral simple mastectomy, PMRT, and subsequent delayed DIEP flap reconstruction (controls)
- Unilateral SSM with temporizing implant, PMRT and subsequent conversion to DIEP (controls)
- Patients of any age will be included
- Patients who are between one and five years post initial breast reconstruction surgery or radiotherapy (which ever is most recent)
Who cannot join
- Women who have undergone bilateral mastectomy, even if the contralateral mastectomy was asynchronous.
- Women who are less than one year from their last radiotherapy treatment or from their DIEP flap reconstruction.
- Patients who have had more than one implant based operation before DIEP flap (revision surgery to the implant implies that an implant based reconstruction was the primary intent and therefore the DIEP flap is a 'salvage' procedure) or if it is documented to be a salvage reconstruction.
- Women who have developed recurrent / distant disease.
- Women who are unable to stand for the 3D imaging (approximately 10 minutes)
- Women who are unable to complete the English language questionnaire or interview (i.e. learning difficulties or patients who do not have adequate English language skills).
- -
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site, 1 recruiting
- Recruiting
The Royal Marsden NHS Foundation Trust
London, London, SW3 6JJ
Lone Gothard, HND, 0044 20 8661 3460, lone.gothard@icr.ac.uk
About this study
Official title: Case Control Study to Evaluate the Impact of Radiotherapy on Patients Undergoing DIEP Flap Breast Reconstruction
The investigators intend to undertake a study to investigate the effect of radiotherapy on deep inferior epigastric perforator flap reconstructions (DIEP). Adjuvant post-mastectomy radiotherapy (PMRT) is offered to women at high risk of chest wall recurrence. The perceived detrimental effect of radiotherapy on an immediate breast reconstruction and the "one-off" nature of autologous reconstruction leads some surgeons to recommend delayed reconstruction after mastectomy or to use a temporising implant with a view to planned exchange to autologous reconstruction after radiotherapy. However, there remains significant uncertainty in the literature about the impact of radiotherapy on autologous reconstructions. This study is a mixed methology study using patient reported outcome measures (PROMS), applanation tonometry (measure of breast compressibility), semi-structured interviews and 3 dimensional photography analysis to compare the aesthetic and impact on quality of life on the following groups of patients:
Patient groups:
- Unilateral skin sparing mastectomy (SSM) with immediate DIEP flap reconstruction and PMRT (cases)
- Unilateral SSM with immediate DIEP flap reconstruction and no PMRT (controls)
- Unilateral simple mastectomy, PMRT, and subsequent delayed DIEP flap reconstruction (controls)
- Unilateral SSM with temporizing implant, PMRT and subsequent conversion to DIEP (controls)
Read the detailed description
Since 1997, breast cancer has been the most common cancer in the UK, accounting for 31% of all new cancers in women. According to the latest statistics published by Cancer Research UK, approximately 50,000 women were diagnosed with breast cancer in 2010(1). In the UK, 53% of women with symptomatic breast cancer and 27% of those with screen-detected breast cancer are treated surgically with mastectomy; therefore approximately 21,500 undergo a therapeutic mastectomy each year (2). Guidelines from the National Institute for Health and Clinical Excellence (NICE) recommend that immediate breast reconstruction is offered to women during the same operation as their mastectomy (3). The UK National Mastectomy and Breast Reconstruction Audit Second Report 2009 (4) states that 21% of their cohort underwent immediate breast reconstruction, thus one would expect approximately 4500 women to undergo immediate reconstruction each year in the UK.
A breast reconstruction should mimic the natural appearance of the breast in shape, volume and compliance, together giving a symmetrical result. Breast reconstruction ranges from implant-based methods to autologous free flap reconstruction, such as the deep inferior epigastric perforator (DIEP) flap, which was first popularised by Allen in 1994(5). In our unit, the DIEP flap has become one of the most reliable and popular methods of breast reconstruction, with flap failure rate of less than 1%. We, like others, view it as the current "gold standard" in breast reconstruction(6)(7)(8).
Adjuvant post-mastectomy radiotherapy (PMRT) is offered to women at high risk of chest wall recurrence. The perceived detrimental effect of radiotherapy on an immediate breast reconstruction and the "one-off" nature of autologous reconstruction leads some surgeons to recommend delayed reconstruction after mastectomy or to use a temporising implant with a view to planned exchange to autologous reconstruction after radiotherapy. However, there remains significant uncertainty in the literature about the impact of radiotherapy on autologous reconstructions . Initially, small case series supported the clinical bias that radiotherapy is detrimental to the autologous reconstruction but, more recently, larger series have challenged this view. Each study has flaws, such as being underpowered, having insufficient duration of follow up, not reporting patient satisfaction or not measuring volume objectively such that residual questions remain. A recent systematic review by Kelley et al attempted to address questions related to complications and flap compromise as a result of radiation delivery before or after autologous breast reconstruction. The review analysed 20 articles with over 1,500 flap reconstructions. No significant differences in measurable postoperative complications including total flap loss, wound healing complications, infection, haematoma, seroma, and fat necrosis were found in comparing patients who underwent PMRT before or after autologous reconstruction. However, differences in cosmetic outcome and patient satisfaction in the irradiated and unirradiated flap reconstruction groups were not adequately addressed.
The heterogeneity of opinion in the literature on the impact of radiotherapy makes patient information and decision-making difficult. It may be that the detrimental effect of radiotherapy is outweighed in terms of patient satisfaction by the benefit of immediate reconstruction with a definitive reconstruction and that surgeons' concerns are overvalued, yet it is upon this anecdotal surgeon-reported outcome that patient decision making is based.
In an era when breast cancer patients are more likely to survive their disease (85% for 5 year survival), the physical and psychological effects of treatment, especially long term effects, are very relevant. A woman with residual dissatisfaction with her reconstructed breast has a constant reminder of her disease and treatment. Optimising reconstructive outcomes is a major issue in survivorship.
Rationale
Surgeons strive to attain the best possible reconstructive outcomes and are aware of the effects of radiotherapy on an autologous flap. They therefore often advise against any procedure which may have a detrimental impact on "their" flap. However, from a patient perspective, by having a delayed reconstruction the treatment pathway is prolonged by several months, if not years, and requires an additional operation(s) compared to those who undergo immediate reconstruction and PMRT. There remains significant uncertainty in the literature about the magnitude of the impact of radiotherapy from a surgeon's perspective and very little is known about the patients' preferences in terms of detrimental impact on flap vs effect of the prolonged pathway on their lives.
By objectively assessing irradiated autologous flap reconstructions and comparing with unirradiated patients we will understand further the impact of radiotherapy on an autologous flap. By quantifying the difference in patient satisfaction, and understanding the perspective of patients who have PMRT to an immediate or delayed reconstruction we will understand further the impact of both pathways on their lives, the reconstruction and their satisfaction with the result. This, we believe, will enable clinicians to better inform patients, empowering them in their decision-making about the best timing for breast reconstruction and potentially enabling more women to undergo immediate definitive breast reconstruction with DIEP flap.
We intend to enrol patients who have undergone unilateral mastectomy and DIEP reconstruction. Patients will fall into one of four possible groups depending on the decision made by the surgeon and patient pre-operatively.
Patient groups:
- Unilateral skin sparing mastectomy (SSM) with immediate DIEP flap reconstruction and PMRT (cases)
- Unilateral SSM with immediate DIEP flap reconstruction and no PMRT (controls)
- Unilateral simple mastectomy, PMRT, and subsequent delayed DIEP flap reconstruction (controls)
- Unilateral SSM with temporizing implant, PMRT and subsequent conversion to DIEP (controls)
The study will be conducted as a mixed methods case control study using both quantitative and qualitative research methods. Initially a prospective study was planned, however for those patients who undergo a delayed reconstruction the whole oncological and reconstructive process can take several years. Secondly the number of patients who are currently undergoing radiotherapy to their DIEP breast reconstruction is relatively small. For these reasons it was decided that a truly prospective study would not be practical but prospective data collection from a recent cohort of patients would yield a greater study population.
- Conditions
- Breast Cancer
- Being tested
- 3D surface imaging, semi-structured interview, applanation tonometry
- Keywords
- breast cancer, mastectomy, deep inferior perforator flap reconstruction, post mastectomy radiotherapy
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
3D surface imagingOther
3D photography
semi-structured interviewOther
qualitative analysis using semi structured interview
applanation tonometryOther
measurement of breast compressibility
| Study group | Role | What they receive |
|---|---|---|
| SSM immediate DIEP | Unilateral skin sparing mastectomy with immediate DIEP Receives: Other: 3D surface imaging; Other: semi-structured interview; Other: applanation tonometry | |
| SSM immediate DIEP and PMRT | Unilateral skin sparing mastectomy with immediate DIEP flap reconstruction and post mastectomy radiotherapy Receives: Other: 3D surface imaging; Other: semi-structured interview; Other: applanation tonometry | |
| mastectomy, PMRT, delayed DIEP | simple mastectomy, post mastectomy radiotherapy adn then delayed DIEP reconstruction Receives: Other: 3D surface imaging; Other: semi-structured interview; Other: applanation tonometry | |
| SSM, temporizing implant, PMRT then DIEP | Unilateral SSM with temporizing implant, PMRT and subsequent Receives: Other: 3D surface imaging; Other: semi-structured interview; Other: applanation tonometry |
What is being measured
The primary outcome is the main question the study is designed to answer.
The difference in patient satisfaction score between patients with an irradiated DIEP flap (group (a)) and patients with a DIEP flap who have not undergone PMRT (group (b)) using "satisfaction with reconstructed breast" question of the BREAST-Q.
The difference in (mean or median) patient satisfaction score (ranging from 0-100) between patients with an irradiated DIEP flap (group (a)) and patients with a DIEP flap who have not undergone PMRT (group (b)) using the "satisfaction with reconstructed breast" subscale of the postoperative reconstruction module of the BREAST-Q questionnaire.
Measured: Day 1
Secondary outcomes (11)
The difference in scores in other subscales from the BREAST-Q questionnaire between patients with an irradiated DIEP flap (group (a)) and patients with a DIEP flap who have not undergone PMRT (group (b)).
Measured: Day 1
The difference in patient satisfaction and all subscales between patients with an irradiated DIEP flap (group (a)) and patients who underwent PMRT prior to DIEP flap (group (c) and group (d)) using BREAST-Q scores as above.
Measured: Day 1
Volume and symmetry assessment of the reconstructed breast using 3D surface imaging This would consist of comparing volume and symmetry assessment between groups (a) and (b), groups (a) and (c), and groups (a) and (d).
Measured: Day 1
Panel assessment by independent panel of the reconstruction using 3D surface imaging.
The panel will consist of four members, a plastic surgeon, a breast surgeon, a clinical oncologist and a breast care nurse. The panel will score independently. The scoring will be between 1 and 4
Measured: Day 1
Applanation tonometry for assessment of the consistency of the reconstructed breast. This will consist of comparing breast compressibility in the reconstructed breast between groups (a) and (b), groups (a) and (c), and groups (a) and (d).
Measured: Day 1
The prevalence of fat necrosis.
The presence of fat necrosis would be either:
Presence of fat necrosis (as documented by imaging) - Yes or no Surgical procedure (excluding biopsy) to treat fat necrosis - Yes or no This would consist of comparing prevalence of fat necrosis and surgical procedures required. Rates of each would be compared between groups (a) and (b), groups (a) and (c), and groups (a) and (d).
Measured: Day 1
The number of operative episodes for the index breast and the contralateral breast.
One visit to theatre counts as one operative episode (i.e. if multiple procedures to the same breast on one occasion then this is still just one operative episode).
This would consist of comparing number of episodes in the index breast and the contra lateral breast between groups (a) and (b), groups (a) and (c), and groups (a) and (d).
Measured: Day 1
Analysis of time from diagnosis to definitive breast reconstruction or last radiotherapy session This would consist of a comparison of number of months treatment between group (a) and group (c), group (a) and group (d).
Measured: Day1
Knowledge of patient experience from interviews regarding patient satisfaction. Please refer to methodology for further details.
Measured: Day 1
Basic health economics of the four treatment groups. This will include cost of each operation/inpatient episodes for all breast related operations and cost of all plastic surgical outpatient events.
Measured: Day 1
Median length of time between end of treatment to time of the study for each of the groups a to d.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2017
- Study start14 Jan 2016
- Primary completion14 Jan 2018 (estimated)
- Study completion14 Jan 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Royal Marsden NHS Foundation TrustThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Royal Marsden NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jennifer Rusby, DM FRCS, Principal investigator, The Royal Marsden Hospital NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03072316
- Sponsor's protocol ID
- CCR 4283
- Status last verified
- Mar 2017
- First submitted
- 13 Apr 2015
- Last updated
- 4 Apr 2017
- Results posted
- No
- Data monitoring committee
- No
Publications
O'Connell RL, Di Micco R, Khabra K, Kirby AM, Harris PA, James SE, Power K, Ramsey KWD, Rusby JE. Comparison of Immediate versus Delayed DIEP Flap Reconstruction in Women Who Require Postmastectomy Radiotherapy. Plast Reconstr Surg. 2018 Sep;142(3):594-605. doi: 10.1097/PRS.0000000000004676.
PubMed 29927832
Study at a glance
From the registry record, last updated by the sponsor on 4 Apr 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Case Control Study to Evaluate the Impact of Radiotherapy on Patients Undergoing DIEP Flap Breast Reconstruction
- ClinicalTrials.gov ID
- NCT03072316
- Acronym / sponsor ID
- CCR 4283
- Conditions
- Breast Cancer
- Keywords
- breast cancer, mastectomy, deep inferior perforator flap reconstruction, post mastectomy radiotherapy
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Royal Marsden NHS Foundation TrustUniversity, hospital or other
- Study start
- 14 Jan 2016
- Primary completion
- 14 Jan 2018 (estimated)
- Study completion
- 14 Jan 2018 (estimated)
- First posted
- 7 Mar 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators intend to undertake a study to investigate the effect of radiotherapy on deep inferior epigastric perforator flap reconstructions (DIEP). Adjuvant post-mastectomy radiotherapy (PMRT) is offered to women at high risk of chest wall recurrence. The perceived detrimental effect of radiotherapy on an immediate breast reconstruction and the "one-off" nature of autologous reconstruction leads some surgeons to recommend delayed reconstruction after mastectomy or to use a temporising implant with a view to planned exchange to autologous reconstruction after radiotherapy. However, there remains significant uncertainty in the literature about the impact of radiotherapy on autologous reconstructions. This study is a mixed methology study using patient reported outcome measures (PROMS), applanation tonometry (measure of breast compressibility), semi-structured interviews and 3 dimensional photography analysis to compare the aesthetic and impact on quality of life on the following groups of patients:
Patient groups:
- Unilateral skin sparing mastectomy (SSM) with immediate DIEP flap reconstruction and PMRT (cases)
- Unilateral SSM with immediate DIEP flap reconstruction and no PMRT (controls)
- Unilateral simple mastectomy, PMRT, and subsequent delayed DIEP flap reconstruction (controls)
- Unilateral SSM with temporizing implant, PMRT and subsequent conversion to DIEP (controls)
Detailed description
Since 1997, breast cancer has been the most common cancer in the UK, accounting for 31% of all new cancers in women. According to the latest statistics published by Cancer Research UK, approximately 50,000 women were diagnosed with breast cancer in 2010(1). In the UK, 53% of women with symptomatic breast cancer and 27% of those with screen-detected breast cancer are treated surgically with mastectomy; therefore approximately 21,500 undergo a therapeutic mastectomy each year (2). Guidelines from the National Institute for Health and Clinical Excellence (NICE) recommend that immediate breast reconstruction is offered to women during the same operation as their mastectomy (3). The UK National Mastectomy and Breast Reconstruction Audit Second Report 2009 (4) states that 21% of their cohort underwent immediate breast reconstruction, thus one would expect approximately 4500 women to undergo immediate reconstruction each year in the UK.
A breast reconstruction should mimic the natural appearance of the breast in shape, volume and compliance, together giving a symmetrical result. Breast reconstruction ranges from implant-based methods to autologous free flap reconstruction, such as the deep inferior epigastric perforator (DIEP) flap, which was first popularised by Allen in 1994(5). In our unit, the DIEP flap has become one of the most reliable and popular methods of breast reconstruction, with flap failure rate of less than 1%. We, like others, view it as the current "gold standard" in breast reconstruction(6)(7)(8).
Adjuvant post-mastectomy radiotherapy (PMRT) is offered to women at high risk of chest wall recurrence. The perceived detrimental effect of radiotherapy on an immediate breast reconstruction and the "one-off" nature of autologous reconstruction leads some surgeons to recommend delayed reconstruction after mastectomy or to use a temporising implant with a view to planned exchange to autologous reconstruction after radiotherapy. However, there remains significant uncertainty in the literature about the impact of radiotherapy on autologous reconstructions . Initially, small case series supported the clinical bias that radiotherapy is detrimental to the autologous reconstruction but, more recently, larger series have challenged this view. Each study has flaws, such as being underpowered, having insufficient duration of follow up, not reporting patient satisfaction or not measuring volume objectively such that residual questions remain. A recent systematic review by Kelley et al attempted to address questions related to complications and flap compromise as a result of radiation delivery before or after autologous breast reconstruction. The review analysed 20 articles with over 1,500 flap reconstructions. No significant differences in measurable postoperative complications including total flap loss, wound healing complications, infection, haematoma, seroma, and fat necrosis were found in comparing patients who underwent PMRT before or after autologous reconstruction. However, differences in cosmetic outcome and patient satisfaction in the irradiated and unirradiated flap reconstruction groups were not adequately addressed.
The heterogeneity of opinion in the literature on the impact of radiotherapy makes patient information and decision-making difficult. It may be that the detrimental effect of radiotherapy is outweighed in terms of patient satisfaction by the benefit of immediate reconstruction with a definitive reconstruction and that surgeons' concerns are overvalued, yet it is upon this anecdotal surgeon-reported outcome that patient decision making is based.
In an era when breast cancer patients are more likely to survive their disease (85% for 5 year survival), the physical and psychological effects of treatment, especially long term effects, are very relevant. A woman with residual dissatisfaction with her reconstructed breast has a constant reminder of her disease and treatment. Optimising reconstructive outcomes is a major issue in survivorship.
Rationale
Surgeons strive to attain the best possible reconstructive outcomes and are aware of the effects of radiotherapy on an autologous flap. They therefore often advise against any procedure which may have a detrimental impact on "their" flap. However, from a patient perspective, by having a delayed reconstruction the treatment pathway is prolonged by several months, if not years, and requires an additional operation(s) compared to those who undergo immediate reconstruction and PMRT. There remains significant uncertainty in the literature about the magnitude of the impact of radiotherapy from a surgeon's perspective and very little is known about the patients' preferences in terms of detrimental impact on flap vs effect of the prolonged pathway on their lives.
By objectively assessing irradiated autologous flap reconstructions and comparing with unirradiated patients we will understand further the impact of radiotherapy on an autologous flap. By quantifying the difference in patient satisfaction, and understanding the perspective of patients who have PMRT to an immediate or delayed reconstruction we will understand further the impact of both pathways on their lives, the reconstruction and their satisfaction with the result. This, we believe, will enable clinicians to better inform patients, empowering them in their decision-making about the best timing for breast reconstruction and potentially enabling more women to undergo immediate definitive breast reconstruction with DIEP flap.
We intend to enrol patients who have undergone unilateral mastectomy and DIEP reconstruction. Patients will fall into one of four possible groups depending on the decision made by the surgeon and patient pre-operatively.
Patient groups:
- Unilateral skin sparing mastectomy (SSM) with immediate DIEP flap reconstruction and PMRT (cases)
- Unilateral SSM with immediate DIEP flap reconstruction and no PMRT (controls)
- Unilateral simple mastectomy, PMRT, and subsequent delayed DIEP flap reconstruction (controls)
- Unilateral SSM with temporizing implant, PMRT and subsequent conversion to DIEP (controls)
The study will be conducted as a mixed methods case control study using both quantitative and qualitative research methods. Initially a prospective study was planned, however for those patients who undergo a delayed reconstruction the whole oncological and reconstructive process can take several years. Secondly the number of patients who are currently undergoing radiotherapy to their DIEP breast reconstruction is relatively small. For these reasons it was decided that a truly prospective study would not be practical but prospective data collection from a recent cohort of patients would yield a greater study population.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| SSM immediate DIEP | – | Other: 3D surface imaging, Other: semi-structured interview, Other: applanation tonometryUnilateral skin sparing mastectomy with immediate DIEP |
| SSM immediate DIEP and PMRT | – | Other: 3D surface imaging, Other: semi-structured interview, Other: applanation tonometryUnilateral skin sparing mastectomy with immediate DIEP flap reconstruction and post mastectomy radiotherapy |
| mastectomy, PMRT, delayed DIEP | – | Other: 3D surface imaging, Other: semi-structured interview, Other: applanation tonometrysimple mastectomy, post mastectomy radiotherapy adn then delayed DIEP reconstruction |
| SSM, temporizing implant, PMRT then DIEP | – | Other: 3D surface imaging, Other: semi-structured interview, Other: applanation tonometryUnilateral SSM with temporizing implant, PMRT and subsequent |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Any patient who has undergone unilateral DIEP reconstruction for breast cancer at the Royal Marsden NHS Foundation Trust
Key inclusion criteria (8 listed)
- Women who have undergone one of the treatment sequences above (a) - (d)
- Patients of any age will be included
- Patients who are between one and five years post initial breast reconstruction surgery or radiotherapy (which ever is most recent)
Key exclusion criteria (7 listed)
- Women who have undergone bilateral mastectomy, even if the contralateral mastectomy was asynchronous.
- Women who are less than one year from their last radiotherapy treatment or from their DIEP flap reconstruction.
- Patients who have had more than one implant based operation before DIEP flap (revision surgery to the implant implies that an implant based reconstruction was the primary intent and therefore the DIEP flap is a 'salvage' procedure) or if it is documented to be a salvage reconstruction.
- Women who have developed recurrent / distant disease.
- Women who are unable to stand for the 3D imaging (approximately 10 minutes)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 3D surface imaging3D photography | Other | SSM immediate DIEP, SSM immediate DIEP and PMRT, SSM, temporizing implant, PMRT then DIEP, mastectomy, PMRT, delayed DIEP |
| semi-structured interviewqualitative analysis using semi structured interview | Other | SSM immediate DIEP, SSM immediate DIEP and PMRT, SSM, temporizing implant, PMRT then DIEP, mastectomy, PMRT, delayed DIEP |
| applanation tonometrymeasurement of breast compressibility | Other | SSM immediate DIEP, SSM immediate DIEP and PMRT, SSM, temporizing implant, PMRT then DIEP, mastectomy, PMRT, delayed DIEP |
Primary outcome
The difference in patient satisfaction score between patients with an irradiated DIEP flap (group (a)) and patients with a DIEP flap who have not undergone PMRT (group (b)) using "satisfaction with reconstructed breast" question of the BREAST-Q.
Time frame: Day 1
The difference in (mean or median) patient satisfaction score (ranging from 0-100) between patients with an irradiated DIEP flap (group (a)) and patients with a DIEP flap who have not undergone PMRT (group (b)) using the "satisfaction with reconstructed breast" subscale of the postoperative reconstruction module of the BREAST-Q questionnaire.
11 secondary outcomes
The difference in scores in other subscales from the BREAST-Q questionnaire between patients with an irradiated DIEP flap (group (a)) and patients with a DIEP flap who have not undergone PMRT (group (b)).
Time frame: Day 1
The difference in patient satisfaction and all subscales between patients with an irradiated DIEP flap (group (a)) and patients who underwent PMRT prior to DIEP flap (group (c) and group (d)) using BREAST-Q scores as above.
Time frame: Day 1
Volume and symmetry assessment of the reconstructed breast using 3D surface imaging This would consist of comparing volume and symmetry assessment between groups (a) and (b), groups (a) and (c), and groups (a) and (d).
Time frame: Day 1
Panel assessment by independent panel of the reconstruction using 3D surface imaging.
Time frame: Day 1
Applanation tonometry for assessment of the consistency of the reconstructed breast. This will consist of comparing breast compressibility in the reconstructed breast between groups (a) and (b), groups (a) and (c), and groups (a) and (d).
Time frame: Day 1
The prevalence of fat necrosis.
Time frame: Day 1
The number of operative episodes for the index breast and the contralateral breast.
Time frame: Day 1
Analysis of time from diagnosis to definitive breast reconstruction or last radiotherapy session This would consist of a comparison of number of months treatment between group (a) and group (c), group (a) and group (d).
Time frame: Day1
Knowledge of patient experience from interviews regarding patient satisfaction. Please refer to methodology for further details.
Time frame: Day 1
Basic health economics of the four treatment groups. This will include cost of each operation/inpatient episodes for all breast related operations and cost of all plastic surgical outpatient events.
Time frame: Day 1
Median length of time between end of treatment to time of the study for each of the groups a to d.
Time frame: Day 1
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Apr 2017.
- Derived from this study: PubMed 29927832O'Connell RL, Di Micco R, Khabra K, Kirby AM, Harris PA, James SE, Power K, Ramsey KWD, Rusby JE. Comparison of Immediate versus Delayed DIEP Flap Reconstruction in Women Who Require Postmastectomy Radiotherapy. Plast Reconstr Surg. 2018 Sep;142(3):594-605. doi: 10.1097/PRS.0000000000004676.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jennifer Rusby, DM FRCS principal investigator
The Royal Marsden Hospital NHS Foundation Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer, run by Royal Marsden NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Rachel O'Connell, MBBSBScMRCS (07786254252, roconnell@doctors.org.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The difference in patient satisfaction score between patients with an irradiated DIEP flap (group (a)) and patients with a DIEP flap who have not undergone PMRT (group (b)) using "satisfaction with reconstructed breast" question of the BREAST-Q. (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03072316, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2017.